NasdaqGS - Delayed Quote
USD
Ionis Pharmaceuticals, Inc. (IONS)
58.09
-0.04
(-0.07%)
At close: September 4 at 4:00:01 PM EDT
52.29
-5.80
(-9.98%)
After hours: September 4 at 7:59:29 PM EDT
Trade IONS on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for IONS
- Previous Close
58.13 - Open
58.36 - Bid 54.01 x 200
- Ask 62.46 x 200
- Day's Range
57.78 - 58.96 - 52 Week Range
50.01 - 86.74 - Volume
2,306,673 - Avg. Volume
3,017,259 - Market Cap (intraday)
9.654B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
-- - EPS (TTM)
-3.48 - Earnings Date Nov 4, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
88.00
Recent News
View More
Performance Overview
Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
IONS
26.57%
S&P 500 (^GSPC)
12.75%
1-Year Return
IONS
2.12%
S&P 500 (^GSPC)
18.71%
3-Year Return
IONS
43.43%
S&P 500 (^GSPC)
70.93%
5-Year Return
IONS
46.99%
S&P 500 (^GSPC)
70.18%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 9/2/2026
-
Market Cap
10.19B
-
Enterprise Value
9.75B
-
Trailing P/E
--
-
Forward P/E
--
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
11.44
-
Price/Book (mrq)
23.18
-
Enterprise Value/Revenue
11.16
-
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
-
Profit Margin
-64.66%
-
Return on Assets (ttm)
-12.43%
-
Return on Equity (ttm)
-105.50%
-
Revenue (ttm)
874.09M
-
Net Income Avi to Common (ttm)
-565.17M
-
Diluted EPS (ttm)
-3.48
Balance Sheet and Cash Flow
-
Total Cash (mrq)
2.1B
-
Total Debt/Equity (mrq)
497.80%
-
Levered Free Cash Flow (ttm)
-346.76M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
Ionis Earnings: Early Signs of Commercial Momentum for Tryngolza as Key Catalysts Approach
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
RatingPrice Target -
Biogen and Ionis: Mixed Phase 2 Data for Alzheimer's Disease Candidate
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
RatingPrice Target -
Biogen and Ionis: Mixed Phase 2 Data for Alzheimer's Disease Candidate
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
RatingPrice Target -
Narrow-Moat Ionis Retains Long-Term Growth Potential Despite Phase 3 ATTR-CM Setback
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
RatingPrice Target
